Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, has been available for the treatment of moderate to severe psoriasis and psoriatic arthritis since February 2015 in Japan. Because there was a time gap after the previous approval of biologics for psoriatic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatology 2021-02, Vol.48 (2), p.175-183
Hauptverfasser:	Fujita, Hideki, Ohtsuki, Mamitaro, Morita, Akimichi, Nagao, Ryuji, Seko, Noriko, Matsumoto, Kazuko, Tani, Yumiko, Terui, Tadashi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antibodies, Monoclonal, Humanized Arthritis Arthritis, Psoriatic - drug therapy Candidiasis effectiveness Humans Japan Monoclonal antibodies Original Patients Psoriasis Psoriasis - drug therapy Psoriasis vulgaris Psoriatic arthritis Quality of life real world Safety secukinumab Severity of Illness Index Side effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!